Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, across generalized Myasthenia Gravis (gMG), Multifocal Motor Neuropathy (MMN) and ...

EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H'28 ...

To survive in the human host, bacteria have developed many different strategies to escape the innate immune response, including the expression of an extracellular capsule and 'hiding' within host ...

Sanofi has stopped a phase 3 autoimmune clinical trial early after an interim analysis found the therapy was “unlikely to provide sufficient efficacy.” The setback eliminates one opportunity for a key ...

Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy Paris, June 10, 2026. Sanofi today announced that the riliprubart MOBILIZE phase ...

The BBC is bringing audiences an unmissable summer of music in 2026, featuring live performances from some of the world’s ...

Sanofi (NASDAQ:SNY) said on Wednesday that it has decided to discontinue the phase 3 MOBILIZE trial evaluating riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who ...

Dianthus Therapeutics Inc. DNTH reported stronger-than-expected midstage results from its CAPTIVATE Phase 3 trial of claseprubart (DNTH103) in chronic inflammatory demyelinating polyneuropathy (CIDP).

Omeros Corporation (Nasdaq: OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company’s marketing ...

By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered: Section 1.  Purpose.

Get inspired to makeover your living spaces this year with these 100 incredible before and after home projects.

Time to get your systems in order, Aquarius. With the Sun in Cancer and your sixth house of health and routines until July 22—and Mercury retrograde here until the 23rd—you’ll be fine-tuning ...